Tim Wade 5/3/22 Tim Wade 5/3/22

PHASE 1 Clinical Trial Complete

We are pleased to announce that MindBio’s scientific team has completed a world-first phase 1 clinical trial microdosing LSD to clinical trial participants who take the drug at home and out in the community in the same way they would take any other medication.

Excerpt from the Market Announcement:

Vancouver, British Columbia – May 3 rd , 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has completed its 12-month Phase 1 clinical trial microdosing LSD in 80 healthy participants. MindBio is developing a microdosing regimen using LSD to treat mental health disorders such as depression. To get these…

Tim Wade 12/15/21 Tim Wade 12/15/21

MindBio to List on CSE

MindBio Therapeutics announces spin out listing from Blackhawk. We are pleased to announce that MindBio has begun preparations to spin out from Blackhawk and list on the Canadian Securities Exchange as a separate entity. Investors in Blackhawk will receive a 1:1 share in MindBio at the record date…

Justin Hanka 12/1/21 Justin Hanka 12/1/21

Big Little Epidemics

Alex Reszelska is a health communications specialist and her educational communications have a focus primarily on families and kids mental health issues.